RxDoctor Payments Data

Belinda Brown Saddler, MD

Family Medicine · Atlanta, GANPI 1588763387

Payments from drug & device makers

$5,064in general payments, 2019–2025

Across 282 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$844
  • Viiv Healthcare Company$627
  • Gilead$444
  • Lilly USA, LLC$399
  • AbbVie$353
  • AstraZeneca$222
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,03499%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,064 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$13,738
Medicare patients
41
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide12$6,832
JanuviaSitagliptin Phosphate11$6,343
Atorvastatin Calcium112$868
Albuterol Sulfate HfaAlbuterol Sulfate25$716
Rosuvastatin Calcium59$660
Losartan Potassium45$489
Levothyroxine Sodium44$465
Amlodipine Besylate97$428
Lisinopril51$338
Gabapentin32$330
Metoprolol Succinate18$288
Omeprazole23$215
Montelukast Sodium24$214
Hydrochlorothiazide36$206
Zolpidem Tartrate21$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$353$6,83212 claims
MerckJanuvia$68$6,34311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →